Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates

Angewandte Chemie - International Edition

Volumn 45, Issue 2, 2005, Pages 285-290

  Hillard, Elizabeth ^a   Vessières, Anne ^a   Thouin, Laurent ^b   Jaouen, Gérard ^a   Amatore, Christian ^b  

^a PSL RESEARCH UNIVERSITY   (France)

^b ECOLE NORMALE SUPÉRIEURE   (France)

Author keywords

Antitumor agents; Electrochemistry; Electron transfer; Hormones; Metallocenes

Indexed keywords

CELLS; DRUG PRODUCTS; ELECTROCHEMISTRY; HORMONES; PROTONS; TUMORS;

ANTITUMOR AGENTS; ELECTRON TRANSFER; METALLOCENES;

ELECTRON TRANSITIONS;

ANTINEOPLASTIC AGENT; FERROCENE; FERROCIFEN; FERROUS ION; PROTON;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ELECTROCHEMISTRY; ELECTRON; HUMAN; HYDROXYLATION; OXIDATION REDUCTION REACTION; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; ELECTROCHEMISTRY; ELECTRONS; FERROUS COMPOUNDS; HUMANS; HYDROXYLATION; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PROTONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29544436942     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200502925     Document Type: Article

References (37)

1. a) S. Bardon, F. Vignon, D. Derocq, H. Rochefort, Mol. Cell. Endocrinol. 1984, 35, 89;
2. b) for recent reviews on the biological mechanisms of SERMs, see: V. C. Jordan, J. Med. Chem. 2003, 46, 883
3. and V. C. Jordan, J. Med. Chem. 2003, 46, 1081.
4. B. K. Keppler, Metal Complexes in Cancer Chemotherapy, VCH, Weinheim, 1993.
5. a) M. J. Clarke, F. Zhu, D. R. Frasca, Chem. Rev. 1999, 99, 2511;
6. b) P. Köpf-Maier, Eur. J. Clin. Pharmacol. 1994, 47, 1.
7. a) S. Top, J. Tang, A. Vessières, D. Carrez, C. Provot, G. Jaouen, Chem. Commun. 1996, 955;
8. b) S. Top, A. Vessières, C. Cabestaing, I. Laios, G. Leclercq, C. Provot, G. Jaouen, J. Organomet. Chem. 2001, 637, 500;
9. c) S. Top, A. Vessières, G. Leclercq, J. Quivy, J. Tang, J. Vaissermann, M. Huché, G. Jaouen, Chem. Eur. J. 2003, 9, 5223;
10. d) G. Jaouen, S. Top, A. Vessières, G. Leclercq, M. J. McGlinchey, Curr. Med. Chem. 2004, 11, 2505.
11. Herein, Cytotoxicity is defined as an antiproliferative effect that, in contrast to an antihormonal effect, is not reversed by the addition of estradiol.
12. a) A. M. Joy, D. M. L. Goodgame, J. I. Stratford, Int. J. Radiat. Oncol. Biol. Phys. 1989, 16, 1053;
13. b) D. Osella, M. Ferrali, P. Zanello, F. Laschi, M. Fontani, C. Nervi, G. Cavigiolio, Inorg. Chim. Acta 2000, 506, 42;
14. c) H. Tamura, M. Miwa, Chem. Lett. 1997, 11, 1177.
15. a) R. L. Sutherland, C. K. W. Watts, R. E. Hall, P. C. Ruenitz, J. Steroid Biochem. 1987, 27, 891, and references therein;
16. b) D. Yao, F. Zhang, L. Yu, Y. Yang, R. B. van Breeman, J. L. Bolton, Chem. Res. Toxicol. 2001, 14, 1643.
17. + moiety.
18. In our system, phenol oxidation waves occurred at potentials higher than 0.8 V vs. SCE.
19. a) C. Amatore, A. Thiébault, J.-N. Verpeaux, J. Chem. Soc. Chem. Commun. 1989, 1543;
20. b) C. Amatore, M. Bayachou, F. Boutejengout, J.-N. Verpeaux, Bull. Soc. Chim. Fr. 1993, 130, 371.
21. C. J. Schlesener, C. Amatore, J. K. Kochi, J. Am. Chem. Soc. 1984, 106, 7472.
22. a) H. C. Brown, D. H. McDaniel, O. Hafliger in Determination of Organic Structures by Physical Methods (Eds.: E. A. Braude, F. C. Nachod), Academic Press, New York, 1955;
23. b) T. C. Bruice, G L. Schmir, J. Am. Chem. Soc. 1958, 80, 148;
24. c) E. Ellenbogen, J. Am. Chem. Soc. 1952, 74, 5198.
25. The involvement of a quinone methide species subsequent to the electron-transfer activation is further supported by the observation that the meio-OH-substituted analogues that have been tested did not show any reactivity following their initial one-electron oxidation in the presence of base (comparable to Figure 3 a), whereas intramolecular electron transfer was observed electrochemically when a para-phenol was added to the meta-substituted derivative, (comparable to Figure 3 b). (P. Pigeon, A. Vessières, E. Hillard, G. Jaouen, unpublished results).
26. a) P. W. Fan, F. Zhang, J. L. Bolton, Chem. Res. Toxicol. 2000, 13, 45;
27. b) F Zhang, P. W. Fan, X. Liu, L. Shen, R. B. van Breeman, J. L. Bolton, Chem. Res. Toxicol. 2000, 13, 53 ;
28. c) S. S. Dehal, D. Kupfer, Cancer Res. 1995, 55, 1283;
29. d) I. R. Hardcastle, M. N. Horton, M. R. Osborne, A. Hewer, M. Jarman, D. H. Phillips, Chem. Res. Toxicol. 1998, 11, 369;
30. e) S. Shibutani, L. Dsaradhi, I. Terashima, E. Banoglu, M. W. Duffel, Cancer Res. 1998, 58, 647;
31. f) L. Dasaradhi, S. Shibutani, Chem. Res. Toxicol. 1997, 10, 189.
32. C. J. Schlesener, C. Amatore, J. K. Kochi, J. Phys. Chem. 1986, 90, 3747.
33. A. Vessières, S. Top, P. Pigeon, E. A. Hillard, L. Boubeker, D. Spera, G. Jaouen, J. Med. Chem. 2005, 48, 3937.
34. A. Vessières, E. A. Hillard, P. Pigeon, S. Top, K. Kowalski, J. Zakrzewski, G. Jaouen, unpublished results. Compounds 4, 7, and 8 were synthesized by McMurry cross-coupling reactions between 3- chloropropionylferrocene and 4,4′-dihydroxybenzophenone, ferrocene ethyl ketone and 4-hydroxy,4′-methoxybenzophenone, and 4-hydroxyphenylethyl ketone and 4-methoxyphenylferrocenyl ketone, respectively, and characterized by NMR spectroscopy and HRMS.
35. D. Plaźuk, A. Vessières, F. Le Bideau, G. Jaouen, J. Zakrzewski, Tetrahedron Lett. 2004, 45, 5425.
36. K. Kowalski, A. Vessières, S. Top, G. Jaouen, J. Zakrzewski, Tetrahedron Lett. 2003, 44, 2749.
37. E. A. Hillard, F. Le Bideau, A. Vessières, D. Plazuk, D. Spera, G. Jaouen, ChemMedChem 2005, submitted.